Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]
MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform […]
Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]
Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company Read more…
Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension. The syndicate comprised its Series B subscribing investors including CRT Pioneer Fund, Claris Ventures, 2Invest, […]
